Stay updated on Pembrolizumab and Epigenetic Drugs in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Epigenetic Drugs in Lung Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and Epigenetic Drugs in Lung Cancer Clinical Trial page
- ChecktodayChange DetectedRevision updated to v3.0.2 from v3.0.1; Back to Top link removed.SummaryDifference0.2%
- Check8 days agoChange DetectedThe web page has been updated to include information on Lung cancer under MedlinePlus Genetics topics, and the version has been revised from v3.0.0 to v3.0.1.SummaryDifference0.4%
- Check15 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed information about lung cancer treatments and related pharmacological terms, while retaining the facility name and location.SummaryDifference2%
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
- Check36 days agoChange DetectedThe page has updated the study dates for the Phase I/Ib study of Pembrolizumab in combination with Guadecitabine and Mocetinostat, moving the timeline forward by a year, and has revised the version number of the document.SummaryDifference2%
- Check43 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.9%
Stay in the know with updates to Pembrolizumab and Epigenetic Drugs in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Epigenetic Drugs in Lung Cancer Clinical Trial page.